[Cl:1][C:2]1[C:7]([F:8])=[CH:6][C:5]([C:9]2[N:10]=[C:11]([N:18]3[CH2:23][CH2:22][NH:21][CH2:20][CH2:19]3)[C:12]3[S:17][CH:16]=[CH:15][C:13]=3[N:14]=2)=[C:4]([F:24])[CH:3]=1.[CH2:25]1[O:27][C@@H:26]1[CH2:28][OH:29].C1COCC1.[ClH:35].O1CCOCC1>CCO>[ClH:1].[ClH:35].[Cl:1][C:2]1[C:7]([F:8])=[CH:6][C:5]([C:9]2[N:10]=[C:11]([N:18]3[CH2:19][CH2:20][N:21]([CH2:25][C@H:26]([OH:27])[CH2:28][OH:29])[CH2:22][CH2:23]3)[C:12]3[S:17][CH:16]=[CH:15][C:13]=3[N:14]=2)=[C:4]([F:24])[CH:3]=1A mixture of 870 mg of 2-(4-chloro-2,5-difluorophenyl)-4-piperazine-1-ylthieno[3,2-d]pyrimidine, 1.08 ml of (R)-glycidol and 15 ml of THF was stirred for 21 hours heated to reflux. The reaction mixture was concentrated under reduced pressure and the obtained residue was purified by silica gel column chromatography (chloroform-MeOH) to give a foam-like substance. After the obtained foam-like substance was dissolved in 10 ml of EtOH and was added to 2 ml of 4M HCl-dioxane solution, it was concentrated under reduced pressure to give a solid. This solid was recrystallized from ethanol to give 898 mg of (S)-3-{4-[2-(4-chloro-2,5-difluorophenyl)thieno[3,2-d]pyrimidine-4-yl]piperazine-1-yl}propane-1,2-diol dihydrochloride.